Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia

NCT01656239 is registered in ClinicalTrials.gov with Vantia Ltd as lead sponsor.

NCT NCT01656239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01656239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia
Lead sponsor
Vantia Ltd
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
September 30, 2013
Enrollment
358 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

nocturia